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Abstract
The Rheb1 and Rheb2 small GTPases and their effector mTOR are aberrantly activated in human 
cancer and are attractive targets for anti-cancer drug discovery. Rheb is targeted to 
endomembranes via its C-terminal CAAX (C = cysteine, A = aliphatic, X = terminal amino acid) 
motif, a substrate for posttranslational modification by a farnesyl isoprenoid. Following 
farnesylation, Rheb undergoes two additional CAAX-signaled processing steps, Rce1-catalyzed 
cleavage of the AAX residues and Icmt-mediated carboxylmethylation of the farnesylated 
cysteine. However, whether these post-prenylation processing steps are required for Rheb 
signaling through mTOR is not known. We found that Rheb1 and Rheb2 localize primarily to the 
endoplasmic reticulum and Golgi apparatus. We determined that Icmt and Rce1 processing is 
required for Rheb localization, but is dispensable for Rheb-induced activation of the mTOR 
substrate p70 S6 kinase (S6K). Finally, we evaluated whether farnesylthiosalicylic acid (FTS) 
blocks Rheb localization and function. Surprisingly, FTS prevented S6K activation induced by a 
constitutively active mTOR mutant, indicating that FTS inhibits mTOR at a level downstream of 
Rheb. We conclude that inhibitors of Icmt and Rce1 will not block Rheb function, but FTS could 
be a promising treatment for Rheb- and mTOR-dependent cancers.
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Introduction
Rheb is a member of the Ras branch of the Ras superfamily of small GTPases and is 
evolutionarily conserved from yeast to humans (Aspuria and Tamanoi, 2004). The two 
mammalian Rheb isoforms, Rheb1 (Rheb) and Rheb2 (RhebL1; 51% identity), function as 
GTP/GDP regulated binary switches. Although both are expressed in many tissues and 
tumor types, current knowledge of Rheb comes largely from the study of Rheb1. Like Ras, 
Rheb proteins cycle between activated, GTP-bound and inactive GDP-bound states. Rheb is 
negatively regulated by the tumor suppressor TSC1 (hamartin)-TSC2 (tuberin) complex 
which functions as a GTPase activating protein (GAP) towards Rheb (Huang and Manning, 
2008).
Rheb is a critical component of the phosphatidylinositol 3-kinase (PI3K)-Akt-TSC-mTOR 
pathway which is frequently hyperactivated in cancer. PI3K activates Akt, which 
phosphorylates and inactivates TSC2, leading to an increase in GTP-bound Rheb (Huang 
and Manning, 2008). Rheb-GTP is an activator of the rapamycin-sensitive mTOR complex 1 
(mTORC1) (Long et al., 2005), which regulates the initiation of protein translation, nutrient 
sensing, and cell growth. mTOR controls protein synthesis by phosphorylating proteins 
involved in translation initiation, such as the p70 ribosomal S6 kinase (S6K).
Loss-of-function germline mutations in TSC1 or TSC2 cause Rheb hyperactivation and 
tuberous sclerosis complex disease which is characterized by the formation of hamartomas 
in a variety of organs (Astrinidis and Henske, 2005; Inoki et al., 2005). Rheb and mTOR are 
also hyperactivated in many sporadic cancers due to mutations in PI3K and PTEN. Rheb1 
and Rheb2 are overexpressed in a variety of tumors, including glioma, oral squamous cell 
carcinoma, and breast, prostate, lung, colon, and ovarian cancer (Basso et al., 2005; 
Chakraborty et al., 2008; Gromov et al., 1995; Jiang and Vogt, 2008; Nardella et al., 2008). 
In addition, a Rheb mutation has been found in colon cancer (Wood et al., 2007), and the 
RHEB gene is amplified in some prostate cancers (Nardella et al., 2008). Therefore, Rheb 
inhibition may be therapeutically beneficial for a variety of cancers.
Like Ras, Rheb terminates in a C-terminal CAAX motif (C = cysteine, A = aliphatic, X = 
terminal amino acid), a substrate for farnesyltransferase (FTase)-catalyzed posttranslational 
modification by a C15 farnesyl isoprenoid lipid (Aspuria and Tamanoi, 2004). Two 
additional CAAX-signaled posttranslational processing steps, proteolytic cleavage of the 
AAX residues [catalyzed by Ras converting enzyme (Rce1)] and carboxylmethylation 
[(catalyzed by isoprenylcysteine carboxyl methyltransferase (Icmt)], are required for Rheb 
localization (Takahashi et al., 2005). However, whether these processing steps are also 
required for Rheb signaling through mTOR is not yet known.
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The CAAX-signaled modifications are necessary but not sufficient for the proper membrane 
association and subcellular localization of a majority of Ras and Rho family small GTPases 
(Cox and Der, 2002; Sebti and Der, 2003). In addition, a second membrane-targeting signal 
positioned in sequences immediately upstream of the CAAX motif is required. For example, 
in H-Ras, the second signal is comprised of two palmitoylated cysteines upstream of the 
CAAX motif, whereas in K-Ras4B and Rac1, it is comprised of polybasic-rich sequences. 
Rheb1 and Rheb2 lack either of these, which may account for the absence of any plasma 
membrane-associated Rheb. However, other unidentified sequence elements may provide a 
second signal (Chenette et al., 2006), so it remains possible that Rheb subcellular 
localization is not dictated solely by CAAX-signaled modifications.
FTase inhibitors (FTIs) are a class of anti-cancer agents that were originally developed to 
inhibit Ras farnesylation and membrane association. While FTIs have shown anti-tumor 
activity, this activity is not due to inhibition of Ras, but rather to inhibition of other FTase 
substrates (Cox and Der, 2002; Sebti and Der, 2003), possibly including Rheb (Basso et al., 
2005; Castro et al., 2003; Mavrakis et al., 2008). Rce1 and Icmt inhibitors, such as 
cysmethynil, are being developed as potential inhibitors of Ras membrane association and 
function (Konstantinopoulos et al., 2007; Winter-Vann and Casey, 2005), but whether they 
block Rheb signaling and function is not known. Additionally, farnesyl-containing small 
molecules, such as S-trans, trans-farnesylthiosalicylic acid (FTS; salirasib), have been 
developed as potential inhibitors of Ras membrane association and are currently undergoing 
clinical evaluation (Blum et al., 2008). Intriguingly, FTS has also exhibited properties of an 
mTOR inhibitor (McMahon et al., 2005; Yue et al., 2007; Yue et al., 2005), but whether this 
is due to inhibition of farnesylated Rheb is not known.
In this study, we determined whether inhibition of CAAX-signaled modifications could be 
used to block aberrant Rheb signaling in cancer. We found that Rheb1 and Rheb2 both 
localized to the endoplasmic reticulum (ER) and Golgi apparatus and that the CAAX motif 
of Rheb1, but not of Rheb2, was sufficient for proper localization. While Rce1- and Icmt-
catalyzed modifications were required for proper Rheb localization, surprisingly, they were 
dispensable for Rheb-mediated activation of mTOR. Finally, we found that FTS directly 
blocked mTOR-induced activation of S6K independently of inhibition of Rheb or other 
prenylated proteins, suggesting that FTS is a novel type of mTOR inhibitor.
Results
Rheb1 and Rheb2 localize to the ER and Golgi
Previous reports indicated that ectopically expressed Rheb1 localizes to the Golgi apparatus 
(Buerger et al., 2006), endoplasmic reticulum (ER) (Jiang and Vogt, 2008), and vesicular 
structures (Buerger et al., 2006; Saito et al., 2005; Sancak et al., 2008), and that endogenous 
Rheb localizes to mitochondria (Ma et al., 2008). The precise subcellular localization of 
Rheb2 has not been described. Therefore, we first wanted to confirm and extend the 
previous disparate observations on Rheb1 and additionally to evaluation Rheb2 localization.
Because no Rheb2 antibody was available for evaluation of endogenous protein, we utilized 
green fluorescent protein (GFP)-tagged Rheb proteins for our analyses. Previous studies 
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with similar GFP-tagged Ras family small GTPases have validated this approach for 
accurate determination of endogenous protein subcellular distribution (Choy et al., 1999; 
Heo and Meyer, 2003; Michaelson et al., 2001). We transiently transfected COS-7 epithelial 
cells with either GFP alone or with GFP-tagged Rheb1 and Rheb2 and treated live cells with 
BODIPY TR C5 ceramide, which detects cis- and trans-Golgi and associated vesicles, as 
well as with MitoTracker, a mitochondrial marker, and LysoTracker, a lysosome marker. In 
addition, we fixed cells and stained with markers of the following intracellular 
compartments: ERp72 (ER), GM130 (cis-Golgi), EEA1 (early endosomes), and LAMP2 
(late endosomes). GFP-Rheb1 and GFP-Rheb2 both exhibited strong colocalization with 
BODIPY TR C5-ceramide (live cells) and GM130 (fixed cells), confirming that they localize 
to the Golgi apparatus (Figures 1a and 1b). GFP-Rheb1 and GFP-Rheb2 also colocalized 
with BODIPY-C5 ceramide in web-like structures in the cytoplasm in live cells (Figure 1a), 
indicative of ER localization (Choy et al., 1999). We also observed colocalization with 
ERp72 in fixed cells, confirming ER localization (Figure 1c). We did not observe 
colocalization of either Rheb1 or Rheb2 with EEA1, LAMP2, LysoTracker, or MitoTracker 
(Supplementary Figure 1), suggesting that Rheb1 and Rheb2 do not localize to early 
endosomes, late endosomes, lysosomes, or mitochondria. We confirmed these results in NIH 
3T3 mouse fibroblasts (data not shown) and we observed similar localization of GFP-Rheb 
in fixed and live cells, although the web-like ER structure was disrupted in fixed cells, as 
observed previously (Choy et al., 1999).
The CAAX motif of Rheb1, but not Rheb2, is sufficient for proper localization
Next, we determined the minimal C-terminal amino acid sequences sufficient for proper 
Rheb localization. Since Rheb proteins lack either a cysteine or a polybasic amino acid-rich 
stretch upstream of their CAAX motifs (Figure 2a), we hypothesized that they lack a 
“second signal” for localization and that the CAAX motif alone would dictate proper 
subcellular localization. To address this possibility, we engineered expression constructs 
encoding the last 4 amino acids of either Rheb1 (CSVM; Rheb1 C4) or Rheb2 (CHLM; 
Rheb2 C4) fused to GFP (Figure 2b). We also created similar constructs with progressively 
longer C-terminal Rheb sequences to determine the minimum membrane targeting sequence 
of Rheb and transiently transfected them into NIH 3T3 cells. As controls, we used GFP-
tagged full-length (FL) Rheb1 and Rheb2, as well as GFP-tagged Rheb1 C181S and Rheb2 
C180S (“SAAX” mutants), which cannot be farnesylated, and hence display a nuclear and 
cytoplasmic localization identical to GFP alone (Figure 2c). Rheb1 C4, C9, and C16 all 
exhibited a subcellular localization indistinguishable from that of full length Rheb1, 
suggesting that the CAAX motif-signaled modifications alone are sufficient for proper 
Rheb1 localization (Figure 2c). Surprisingly, Rheb2 C4 did not localize to the distinct 
perinuclear region as seen with full length Rheb2, but instead exhibited a more diffuse 
cytoplasmic localization, and indicating that it was partially mislocalized, but still distinct 
from the localization of the unfarnesylated SAAX mutant. In contrast, Rheb2 C8 displayed a 
localization identical to the full length protein, suggesting that amino acid residues 
immediately upstream of the CAAX motif are required for proper Rheb2 localization to the 
Golgi.
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Localization of farnesylated Rheb is more dependent on Rce1- and Icmt-catalyzed 
modifications than geranylgeranylated Rheb
A previous study showed that Rheb1 localization is impaired in MEFs lacking Rce1 or Icmt, 
but whether Rheb1 function was impaired in these MEFs was not addressed (Takahashi et 
al., 2005). To determine if Rheb1-mediated activation of mTORC1 was dependent on these 
modifications, we first sought to confirm these localization findings, and to extend them to 
Rheb2. We transiently transfected wild-type (Rce1 +/+ and Icmt +/+), Rce1-deficient (Rce1 
−/−), and Icmt-deficient (Icmt −/−) MEFs with expression vectors encoding GFP-Rheb1 and 
GFP-Rheb2. We recently utilized this set of MEFs and verified that the subcellular 
localication of GFP-tagged versions of Ras and Rho proteins accurately corresponded to the 
localization of their endogenously-expressed counterparts (Roberts et al., 2008). The 
localization of GFP-Rheb1 and GFP-Rheb2 was identical in two independent isolates of 
wild-type MEFs (Figure 3a). Consistent with previous results for Rheb1 (Takahashi et al., 
2005), we found that the normal localization of both Rheb1 and Rheb2 was completely 
impaired in Icmt −/− MEFs. Both Rheb1 and Rheb2 showed significant nuclear 
accumulation and were indistinguishable from the subcellular distribution of GFP alone 
(Figures 3a and 3b). Rce1 deficiency is expected to prevent the subsequent Icmt 
modification. However, Rheb1 and Rheb2 were only partially mislocalized in Rce1 −/− 
MEFs: Rheb1 and Rheb2 accumulated in the nucleus and cytosol, but Golgi localization was 
still visible (Figures 3a and 3b). Thus, Rheb1 and Rheb2 are more dependent on Icmt-
mediated methylation than on Rce1-mediated AAX cleavage, a pattern that we have 
observed with other farnesylated small GTPases (Roberts et al., 2008). We also observed an 
increase in the cytosolic fraction of endogenous Rheb1 in Rce1 −/− and Icmt −/− MEFs by 
subcellular fractionation (data not shown).
The CAAX motifs of some GTPases, particularly Rho GTPases, are substrates for 
geranylgeranyltransferase-I (GGTase-I)-catalyzed addition of a longer C20 geranylgeranyl 
isoprenoid lipid. A previous study found that the localization of geranylgeranylated proteins 
is less dependent on Rce1- and Icmt-catalyzed modifications than farnesylated protein 
localization (Michaelson et al., 2005). Whether modification by the more hydrophobic 
geranylgeranyl group also reduces Rheb sensitivity to Icmt and Rce1 loss was not known. 
To obtain geranylgeranylated Rheb (GG-Rheb) mutants, we mutated the C-terminal amino 
acid of Rheb1 and Rheb2 from methionine to leucine (Rheb1 M184L and Rheb2 M183L). 
Similar CAAX mutants of S. pombe and human Rheb showed FTase-independent function 
(Basso et al., 2005; Gau et al., 2005; Mavrakis et al., 2008; Nakase et al., 2006). We utilized 
pharmacologic inhibitors of FTase and GGTase-I (GGTI) and confirmed that GG-Rheb was 
less sensitive to inhibition by FTI than wild-type farnesylated Rheb (F-Rheb; data not 
shown).
To determine whether localization of GG-Rheb also depends on Rce1- and Icmt-catalyzed 
modifications, we transiently transfected wild-type, Rce1 −/−, and Icmt −/− MEFs with 
GFP-tagged GG-Rheb1 and GG-Rheb2. As expected, in wild-type MEFs, GG-Rheb2 
displayed identical subcellular localization to F-Rheb. However, we were surprised to find 
that GG-Rheb1 localization was similar to that seen with wild type F-Rheb1 in only a subset 
of cells. Instead, a majority (74–77%) of GG-Rheb1 expressing cells showed partially (48–
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66%) or completely (11–26%) mislocalized distributions (Figures 3a and 3b). Thus, unlike 
most Ras and Rho small GTPases, where the type of isoprenoid modification did not alter 
protein localization, geranylgeranyl modification did not substitute for farnesylation to fully 
support Rheb1 subcellular localization.
In Rce1 −/− MEFs, F-Rheb1 and GG-Rheb1 were partially mislocalized (74–76%) (Figure 
3b). However, when expressed in Icmt −/− MEFs, a much lower percentage (48%) of GG-
Rheb1 was completely mislocalized when compared to F-Rheb1 (95%). Similarly, a 
majority of GG-Rheb2 (>50%) retained proper localization in both Rce1 −/− and Icmt −/− 
cells, although all of the F-Rheb2 was partially or completely mislocalized in these cells. 
Thus, modification by a geranylgeranyl group reduces the requirement of both Rheb1 and 
Rheb2 for the subsequent CAAX modifications, particularly by Icmt.
Rheb activation of mTOR is more dependent on farnesylation than on postprenylation 
CAAX processing
Since Rheb1 and Rheb2 are mislocalized in the absence of Rce1 and Icmt, we asked if Rheb 
signaling was impaired in Rce1 −/− and Icmt −/− MEFs. First, we wanted to confirm in our 
assays that Rheb activation of mTOR is dependent on farnesylation (Buerger et al., 2006). 
We transfected wild-type or knockout MEFs with constructs encoding GFP-tagged fusion 
proteins of an activated mutant of Rheb1 (Q64L) with an intact CAAX sequence or with two 
CAAX missense mutants: a geranylgeranylated variant (X=L; M184L), designated GG-
Rheb1, and a nonfarnesylated mutant (C=S; C181S), designated Rheb1-SAAX. As 
expected, both F-Rheb and GG-Rheb efficiently induced S6K phosphorylation in wild-type 
Icmt +/+ MEFs (Figure 4a). We obtained similar results in Rce1 +/+ MEFs (data not shown). 
In agreement with previous observations (Basso et al., 2005; Buerger et al., 2006; Clark et 
al., 1997), we found that the nonfarnesylated Rheb1-SAAX mutant was greatly impaired in 
stimulating S6K phosphorylation.
Since Rheb1-SAAX fails to undergo all three CAAX-signaled modifications, we next 
determined a role for the Rce1- and Icmt-catalyzed modifications in Rheb1 function. 
Surprisingly, both F-Rheb and GG-Rheb retained the ability to stimulate S6K 
phosphorylation when expressed in either Rce1 −/− or Icmt −/− MEFs (Figure 4a).
Since these observations were unexpected, we also compared the activity of Rheb1 with a 
different N-terminal tag (FLAG) and activating mutation (N153T) (Urano et al., 2005) with 
that of constitutively activated K-Ras4B(G12V), which is expected to require these 
modifications, and with that of constitutively activated mTOR (E2419K; a kinase-domain 
mutation) (Urano et al., 2007), which is not a substrate for either CAAX modifying enzyme. 
We transiently transfected wild-type, Rce1 −/−, and Icmt −/− MEFs with either pcDNA3 
empty vector, or with pcDNA3 encoding constitutively activate mutants of K-Ras (HA-K-
Ras G12V), Rheb1 (FLAG-Rheb N153T), or mTOR (AU1-mTOR E2419K), along with 
pRK7 HA-S6K1, and used western blot analysis to determine S6K phosphorylation. 
Consistent with previous studies (Sato et al., 2008; Urano et al., 2005; Urano et al., 2007), 
we observed that activated K-Ras4B, Rheb1, and mTOR all efficiently induced 
phosphorylation of S6K in wild type MEFs. As expected, since mTOR is not a substrate for 
Rce1 and Icmt, constitutively active mTOR also induced S6K phosphorylation in Rce1 −/− 
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and Icmt −/− cells (Figure 4b). Unexpectedly, K-Ras4B also did not show impaired S6K 
phosphorylation when expressed in Rce1 −/− or Icmt −/− MEFs. However, this result is 
consistent with our recent observation that K-Ras4B subcellular localization and plasma 
membrane association were not impaired to any significant degree in Rce1- or Icmt-null 
cells (Roberts et al., 2008). Consistent with GFP-tagged Rheb1, FLAG-tagged Rheb-
induced S6K phosphorylation was also not impaired in Rce1 −/− or Icmt −/− MEFs. Thus, 
while these CAAX modifications are necessary for proper subcellular localization, Rheb 
activation of mTOR is not impaired in the absence of Rce1 or Icmt function. Taken together, 
these data suggest that Rheb activation of mTOR is more dependent on farnesylation than on 
Rce1- and Icmt-catalyzed modifications.
Postprenylation CAAX processing is not required for activation of mTOR signaling by 
endogenous Rheb
The above results suggested that Rce1- and Icmt-catalyzed modifications are required for 
Rheb localization, but not for Rheb activation of mTOR. However, the above experiments 
were performed using ectopically expressed Rheb protein, which may not accurately reflect 
endogenous Rheb activity. Therefore, to determine whether endogenous Rheb activation is 
impaired in the absence of Rce1 and Icmt, we stably infected wild-type, Rce1 −/−, and Icmt 
−/− MEFs with a previously described short hairpin RNA (shRNA) targeting mouse TSC2 
(Peterson et al., 2009), encoding the Rheb GAP catalytic subunit. The TSC2 shRNA 
strongly reduced endogenous TSC2 expression in all MEFs (Figure 4c). As expected, in 
both isolates of wild-type MEFs, knocking down TSC2 increased phosphorylation of S6K 
and its substrate, the ribosomal subunit S6 (Figure 4c). Similarly, phosphorylation of S6K 
and S6 was increased in Rce1 −/− and Icmt −/− MEFs expressing TSC2 shRNA. These 
results are consistent with our experiments performed using ectopically expressed Rheb and 
suggest that Rce1- and Icmt-catalyzed modifications are not required for activation of 
endogenous Rheb-mTOR signaling.
FTS does not disrupt the subcellular localization of Rheb
FTS (also called salirasib) is a farnesylcysteine mimetic that is proposed to dislodge Ras 
proteins from the plasma membrane and thus inhibit Ras activity (Blum et al., 2008; Kloog 
and Cox, 2004). However, whether FTS also displaces and inhibits the function of other 
farnesylated proteins, such as Rheb, is not known. FTS has also been shown to reduce 
phosphorylation of the mTOR substrates S6K and 4E-BP1 (Yue et al., 2007; Yue et al., 
2005), but whether this is due to Rheb inhibition was not investigated. To determine if FTS 
inhibits Rheb localization, we transiently expressed GFP-tagged Rheb1 or YFP-tagged H-
Ras in NIH 3T3 cells and treated them with FTS. As a control, we treated cells with 
FTI-2153, since FTIs are known to impair Rheb and H-Ras localization (Buerger et al., 
2006; Roberts et al., 2008; Takahashi et al., 2005). Indeed, GFP-Rheb and YFP-H-Ras were 
completely mislocalized in FTI-treated cells (Figure 5). Surprisingly, FTS did not cause 
mislocalization of either H-Ras or Rheb. We obtained similar results with endogenous Rheb 
and Ras subcellular localization when evaluated by subcellular fractionation (data not 
shown). These results suggest that FTS does not detectably disrupt the membrane 
association and subcellular localization of Rheb or Ras proteins under these conditions.
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FTS inhibits mTOR-induced S6K activation and reduces mTOR protein levels
Since it remained possible that FTS may disrupt Rheb interaction with mTOR, we next 
asked if FTS inhibits Rheb-induced activation of mTOR. Activated K-Ras4B, Rheb1, and 
mTOR all efficiently induced S6K phosphorylation in vehicle (DMSO)-treated cells (Figure 
6a). As expected, FTI treatment strongly inhibited Rheb1-induced S6K phosphorylation and 
resulted in a shift in Rheb mobility as seen by SDS-PAGE, indicating the accumulation of 
unprenylated Rheb1. We also observed an increase in Rheb protein levels in FTI-treated 
cells, in agreement with previous studies (Buerger et al., 2006). Importantly, FTI treatment 
did not block mTOR-induced S6K phosphorylation, since mTOR E2419K is constitutively 
active and is not dependent on Rheb. In contrast, FTS strongly inhibited K-Ras, Rheb, and 
mTOR-induced S6K phosphorylation, suggesting that FTS inhibits S6K activation at the 
level of mTOR, and not by inhibiting upstream activators.
Surprisingly, we found that FTS treatment of NIH 3T3 cells decreased levels of both 
endogenous and ectopically expressed mTOR protein (Figure 6a), but did not decrease 
levels of K-Ras, Rheb, or β-actin. Thus, FTS inhibition of mTOR may be due, in part, to 
promoting the loss of mTOR protein. However, FTS treatment did not decrease endogenous 
mTOR in MCF-7 human breast carcinoma cells, whereas it did decrease phospho-S6K in 
these cells (Figure 7, discussed below), suggesting that the FTS-induced reduction in mTOR 
levels is not the primary cause of the reduction in S6K phosphorylation.
FTS inhibition of mTOR does not require protein prenylation
One explanation for the above results could be that FTS is blocking the function of an 
unidentified prenylated protein required for mTOR-induced S6K phosphorylation. For 
example, Cdc42 and Rac1, which are geranylgeranylated, have previously been implicated 
in S6K phosphorylation (Chou and Blenis, 1996). In addition, RalA, another 
geranylgeranylated protein, was recently shown to be required for Rheb-induced S6K 
phosphorylation (Maehama et al., 2008). To determine whether prenylated proteins are 
required for mTOR-induced S6K phosphorylation, we transiently transfected NIH 3T3 cells 
as described above, and treated cells with FTI, a GGTase-I inhibitor (GGTI), or both. We 
verified that the GGTI was functional and inhibited modification of Rap1A (Figure 6b). As 
expected, FTI inhibited Rheb1-induced, but not mTOR-induced, S6K phosphorylation 
(Figure 6b). Combined treatment with FTI and GGTI efficiently inhibited K-Ras4B-induced 
S6K phosphorylation, presumably as a consequence of blocking alternative prenylation of 
K-Ras4B (Rowell et al., 1997; Whyte et al., 1997). In contrast, FTI and GGTI in 
combination failed to prevent mTOR-induced S6K phosphorylation, suggesting that 
prenylated proteins modified by either farnesyltransferase or GGTase-I are not required for 
mTOR activation of S6K.
To confirm these results and to exclude the possibility that prenylated GGTase-II substrates 
(such as Rab GTPases) are required for mTOR activation of S6K, we treated cells with 
lovastatin, which blocks all protein prenylation. As expected, lovastatin treatment caused a 
mobility shift in Rheb, and reduced both Rheb- and K-Ras-induced S6K phosphorylation 
(Figure 6c). However, lovastatin failed to inhibit mTOR-induced S6K phosphorylation. 
Thus, FTS inhibition of mTOR does not involve inhibition of a prenylated protein.
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FTS inhibits endogenous S6K activity in breast cancer cells
As described previously (Yue et al., 2007), we confirmed that FTS inhibited endogenous 
S6K activity in MCF-7 cells, but treatment did not affect mTOR or Rheb1 protein levels 
(Figure 7). These data are consistent with the hypothesis that FTS is an mTOR inhibitor.
Discussion
Rheb functions as a key intermediate in the PI3K-AKT-TSC-Rheb-mTOR network that is 
aberrantly activated in a majority of human cancers (Cully et al., 2006). While 
pharmacologic inhibitors of PI3K, AKT and mTOR are currently in Phase I/II clinical trials, 
Rheb may also be a useful target. A key goal of our study was to determine if specific 
approaches can block Rheb function by disrupting the membrane association and subcellular 
distribution of Rheb essential for its biological activity. We assessed two different strategies 
for blocking Rheb function. The first strategy involves preventing the CAAX-mediated 
posttranslational modifications that promote Rheb membrane association. We found that 
both Rheb1 and Rheb2 localization, but not mTOR activation, was disrupted in the absence 
of the post-prenylation processing enzymes Rce1 or Icmt, suggesting that inhibitors of these 
enzymes will not block Rheb signaling and oncogenic activity. The second strategy involves 
inhibition of Rheb endomembrane association by FTS. Unexpectedly, we found that FTS 
did not effectively impair Rheb or Ras protein membrane association. Instead, we found that 
FTS blocked Rheb activation of mTOR, but this effect was independent of inhibition of 
Rheb or of any other prenylated protein. Rather, we suggest that a potent mechanism for 
FTS-mediated growth inhibition may involve direct inhibition of mTOR.
Although the subcellular localization of Rheb proteins has been addressed in multiple 
previous studies, conflicting observations were made (Buerger et al., 2006; Jiang and Vogt, 
2008; Ma et al., 2008; Sancak et al., 2008; Takahashi et al., 2005). Furthermore, the precise 
subcellular localization of Rheb2 had not been determined. We confirmed that Rheb1 is 
primarily localized to the Golgi and ER endomembranes, in agreement with others (Buerger 
et al., 2006; Jiang and Vogt, 2008). We also found that the localization of Rheb2 is 
indistinguishable from that of Rheb1, and that Rheb localization overlaps with the observed 
localization of Rheb binding partners (Drenan et al., 2004; Du et al., 2003; Wienecke et al., 
1996). The essentially identical subcellular localization of Rheb1 and Rheb2 contrasts with 
the situation seen with closely related isoforms of other Ras family small GTPases. For 
example, although RalA and RalB share 82% overall sequence identity, their distinct 
subcellular distributions result in strikingly distinct biological roles (Bodemann and White, 
2008).
We found that, unlike most Ras and Rho small GTPases, the CAAX motif alone of Rheb1 
was sufficient for proper localization. These data are consistent with Choy et al., who 
showed that the CAAX motif of K-Ras and N-Ras alone promoted localization to the ER 
and Golgi (Choy et al., 1999). In contrast, the CAAX motif alone was not sufficient for 
proper localization of Rheb2, which required amino acids immediately upstream of the 
CAAX motif, suggesting that the targeting motifs of Rheb1 and Rheb2 are not functionally 
identical.
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We also found that geranylgeranylated mutants of Rheb1 and Rheb2 (Rheb1 M184L and 
Rheb2 M183L), like their farnesylated wild-type counterparts, localized to the ER and 
Golgi. However, the localization of GG-Rheb was less dependent on Icmt- and Rce-1 
catalyzed modifications, in agreement with previous studies showing that the localization of 
geranygeranylated Ras mutants was less dependent on these modifications than farnesylated 
Ras (Michaelson et al., 2005).
Farnesylation of Rheb was required for its ability to activate mTOR, as shown by the 
inability of the nonfarnesylated SAAX mutant of Rheb1 to induce S6K phosphorylation. 
These observations are consistent with several studies showing that FTI impairs S6K or S6 
phosphorylation (Basso et al., 2005; Gau et al., 2005; Law et al., 2000; Mavrakis et al., 
2008). In contrast, although Rce and Icmt were required for proper Rheb localization, 
neither of the post-prenyl processing steps was required for Rheb-induced mTOR activation. 
These results are surprising, since they suggest that Rheb does not need to be localized 
properly in order to activate mTOR. Future experiments should determine whether co-
immunoprecipitation of endogenous Rheb and mTOR is disrupted in the absence of Rce1 
and Icmt. Although signaling pathway activation can vary substantially between 
independently immortalized MEF cell lines, we observed identical results in two different 
wild-type MEF isolates. Furthermore, we found that the Icmt inhibitor cysmethynil did not 
block Rheb activation of mTOR (data not shown). These data are consistent with those of 
Buerger et al., who showed that the methyltransferase inhibitor AFC does not block Rheb-
induced S6K activation (Buerger et al., 2006). Therefore, we predict that inhibitors of Rce1 
and Icmt will not inhibit Rheb activity.
We found that FTS strongly inhibited both Rheb- and mTOR-induced S6K activation. FTS 
is proposed to compete with farnesylated Ras for membrane binding sites and dislodge Ras 
from the membrane, thereby disrupting its function (Haklai et al., 1998; Marom et al., 1995; 
Rotblat et al., 2008; Weisz et al., 1999). However, we failed to observe detectable disruption 
of H-Ras or Rheb membrane association. Instead, our data strongly suggest that the FTS-
mediated inhibition of mTOR-induced S6K activation is not due to inhibition of a prenylated 
protein. Rather, our data are consistent with the observation that FTS disrupts the association 
of mTOR with raptor (McMahon et al., 2005). We failed to observe a concomitant decrease 
in Akt phosphorylation on S473 in FTS-treated cells (data not shown), suggesting that FTS 
inhibits mTORC1 but not mTOR complex 2 (mTORC2) activity.
In summary, we have found that inhibition of Rce1- and Icmt-catalyzed modifications does 
not prevent Rheb activation of mTOR, and that FTS inhibits mTOR through a mechanism 
that does not involve Rheb inhibition. Although FTS is not a direct Rheb inhibitor, mTOR is 
essential for Rheb oncogenic activity (Jiang and Vogt, 2008; Mavrakis et al., 2008); hence, 
FTS would be expected to disrupt both Rheb- and mTOR-induced transformation. Since 
FTS is currently in clinical trials for cancer treatment, our results have significant 
implications for the selection of patients who may benefit from FTS therapy and suggest that 
S6K phosphorylation may be a useful biomarker to monitor FTS activity.
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Figure 1. Rheb1 and Rheb2 are localized primarily to the ER and Golgi. COS-7 cells were 
transiently transfected with pEGFP vector or with pEGFP encoding GFP-tagged Rheb1 or 
Rheb2
(a) Rheb localization in cis- and trans-Golgi and associated endomembranes. Live cells 
were imaged after staining with BODIPY TR C5 ceramide. (b) Rheb localization in cis-
Golgi. Cells were fixed and immunostained with mouse anti-GM130 antibody followed by 
Alexa Fluor 594-conjugated anti-mouse secondary antibody. (c) Rheb localization in the ER. 
Cells were fixed and immunostained with rabbit anti-ERp72 antibody followed by Alexa 
Fluor 594-conjugated anti-rabbit secondary antibody. All images were acquired on a Zeiss 
Hanker et al. Page 15













confocal microscope using LSM software. Data shown are representative of more than 10 
images from at least two independent experiments.
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Figure 2. CAAX-signaled modifications alone are sufficient for Rheb1 but not Rheb2 subcellular 
localization to the ER and Golgi
(a) Comparison of C-terminal membrane targeting sequence elements of H-Ras, K-Ras4B, 
Rnd3, Rheb1, and Rheb2. Palmitoylated cysteines (in H-Ras) and polybasic residues (in K-
Ras 4B and Rnd3) are underlined. The C-terminal CAAX motifs are shaded. (b) GFP fusion 
proteins terminating in the Rheb1 or Rheb2 C-terminal sequences shown were encoded by 
cDNA sequences subcloned into the pEGFP vector. (c) NIH 3T3 cells were transiently 
transfected with pEGFP vector, or with pEGFP encoding the following proteins: GFP-
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tagged full-length Rheb1 C181S (Rheb1 SAAX), full-length Rheb2 C180S (Rheb2 SAAX), 
the indicated C-terminal Rheb1 or Rheb2 sequences, or full-length (FL) Rheb1 or Rheb2. 
Live cells were imaged by confocal microscopy. Data shown are representative of two 
independent experiments.
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Figure 3. Rheb subcellular localization is dependent on Rce1- and Icmt-catalyzed modifications
(a) Rce1 +/+, Rce1 −/−, Icmt +/+, and Icmt −/− MEFs were transiently transfected with 
pEGFP vector or with pEGFP encoding GFP-tagged Rheb1 (F-Rheb1), Rheb1 M184L (GG-
Rheb1), Rheb2 (F-Rheb2), or Rheb2 M183L (GG-Rheb2). Live cells were imaged by 
confocal microscopy. (b) Quantification of the data shown in (a). At least 30 cells in each 
condition were scored.
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Figure 4. Rce1- and Icmt-catalyzed modifications are not required for Rheb1 activation of S6K
(a) Wild-type (Icmt +/+) Rce1 −/−, and Icmt −/− mouse embryo fibroblasts were transiently 
transfected with pEGFP vector or with pEGFP encoding Rheb1 Q64L (F-Rheb1 64L), 
Rheb1 M184L/Q64L (GG-Rheb1 64L), or Rheb1 C181S/Q64L (Rheb1-SAAX 64L), along 
with pRK7 HA-S6K1, and serum- and amino-acid starved as described in Materials & 
Methods. Cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies to 
phospho-S6K, HA, GFP, or β-actin (loading control). (b) Wild-type (Icmt +/+), Rce1 −/−, 
and Icmt −/− MEFs were transiently transfected with pcDNA3 vector, or with pcDNA3 
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encoding HA-tagged K-Ras G12V, FLAG-tagged Rheb1 N153T, or AU1-tagged mTOR 
E2419K, along with pRK7 HA-tagged S6K1, and serum- and amino acid-starved as in (a). 
Cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies to phospho-
S6K, HA, Rheb1, K-Ras, or β-actin (loading control). (c) Rce1 +/+, Rce1 −/−, Icmt +/+, and 
Icmt −/− MEFs were stably infected with either non-specific shRNA (NS) or shRNA 
targeting mouse TSC2 (TSC2 sh). Cells were lysed 5 d post-infection and lysates were 
immunoblotted with antibodies to TSC2, phospho-S6K, total S6K, phospho-S6, total S6, or 
Rheb1. Data shown are representative of at least two independent experiments.
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Figure 5. FTS does not disrupt Rheb or H-Ras subcellular localization
(a) NIH 3T3 cells were transiently transfected with pEGFP vector, pEGFP encoding GFP-
tagged Rheb1, or pEYFP encoding YFP-tagged H-Ras and treated with DMSO (Vehicle), 5 
µM FTI-2153, or 75 µM FTS overnight. Live cells were imaged by confocal microscopy.
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Figure 6. FTS inhibits mTOR-induced S6K activation by a mechanism independent of 
prenylated proteins
(a) NIH 3T3 cells were transiently transfected with pcDNA3 vector, or with pcDNA3 
encoding HA-tagged K-Ras G12V, FLAG-tagged Rheb1 N153T, or AU1-tagged mTOR 
E2419K, along with pRK7 HA-tagged S6K1. Three h following transfection, medium was 
replaced with complete medium containing either DMSO (Vehicle) or 5 µM FTI-2153. 
Twenty-four h following transfection, cells were serum-starved in DMEM supplemented 
with 0.1% BSA containing DMSO, 5 µM FTI-2153, or 75 µM FTS overnight, and then 
amino-acid starved in PBS containing the indicated compound for 1 h. Cell lysates were 
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resolved by SDS-PAGE and immunoblotting was performed with antibodies to phospho-
S6K, HA, Rheb1, K-Ras, or β-actin (loading control). Data are representative of three 
independent experiments. (b) NIH 3T3 cells were transiently transfected with the indicated 
plasmids, as described above. Three h following transfection, medium was replaced with 
complete medium supplemented with DMSO, 10 µM FTI-2153, 20 µM GGTI-2417, or 10 
µM FTI + 20 µM GGTI. Cells were serum- and amino-acid starved as in (a). Cell lysates 
were resolved by SDS-PAGE and immunoblotting was performed with antibodies to 
phospho-S6K, HA, Rheb1, K-Ras, Rap1, or β-actin (loading control). (c) NIH 3T3 cells 
were transiently transfected with the indicated plasmids. Three h following transfection, 
medium was replaced with complete medium supplemented with DMSO (Vehicle), 10 µM 
FTI-2153, 20 µM lovastatin, or 30 µM lovastatin. Serum- and amino acid-starved cell lysates 
were resolved by SDS-PAGE and immunoblotting was performed with antibodies to 
phospho-S6K, HA, Rheb1, K-Ras, H-Ras, or β-actin (loading control). Data shown are 
representative of at least two independent experiments.
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Figure 7. FTS blocks endogenous S6K activation in MCF-7 cells
MCF-7 cells growing in complete medium were treated with 100 µM FTS in complete 
medium for 0, 2, 6, 16, or 24 h. Cell lysates were resolved by SDS-PAGE and 
immunoblotted with antibodies to phospho-S6K, total S6K, phospho-S6, total S6, mTOR, 
and β-actin (loading control). Data shown are representative of two independent 
experiments.
Hanker et al. Page 25
Oncogene. Author manuscript; available in PMC 2010 July 21.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
